BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37628606)

  • 1. Mutations of
    Tsyganov MM; Sorokovikova SS; Lutzkaya EA; Ibragimova MK
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    Hamid AB; Frank LE; Bouley RA; Petreaca RC
    PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
    Tsyganov MM; Ibragimova MK; Garbukov EY; Bragina OD; Karchevskaya AA; Usynin EA; Litvyakov NV
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Donenberg T; Ahmed H; Royer R; Zhang S; Narod SA; George S; Akbari MR; Ali J; Hurley J
    Breast Cancer Res Treat; 2016 Aug; 159(1):131-8. PubMed ID: 27469594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
    Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
    PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
    Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
    Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
    J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
    Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
    Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
    Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
    Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
    PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
    Lerner-Ellis J; Donenberg T; Ahmed H; George S; Wharfe G; Chin S; Lowe D; Royer R; Zhang S; Narod S; Hurley J; Akbari MR
    Breast Cancer Res Treat; 2017 Apr; 162(3):591-596. PubMed ID: 28194609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.